ArticleScience translational medicine2012
AAV-directed persistent expression of a gene encoding anti-nicotine antibody for smoking cessation.
Article in Science translational medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Nicotine vaccines for smoking cessation.The Cochrane database of systematic reviews · 2012Pooled it
- Investigation of dose-exposure-response relationship for adeno-associated virus-mediated delivery of antibody genes.The Journal of pharmacology and experimental therapeutics · 2025Article
- Optimization strategies and advances in the research and development of AAV-based gene therapy to deliver large transgenes.Clinical and translational medicine · 2024Review
- Attenuating nicotine's effects with high affinity human anti-nicotine monoclonal antibodies.PloS one · 2021Article
- The Development and Characterization of an scFv-Fc Fusion-Based Gene Therapy to Reduce the Psychostimulant Effects of Methamphetamine Abuse.The Journal of pharmacology and experimental therapeutics · 2020Article
- Monoclonal Antibodies for Combating Synthetic Opioid Intoxication.Journal of the American Chemical Society · 2019Article
- Gene delivery of a modified antibody to Aβ reduces progression of murine Alzheimer's disease.PloS one · 2019Article
- Development and testing of AAV-delivered single-chain variable fragments for the treatment of methamphetamine abuse.PloS one · 2018Article
- THE JEREMIAH METZGER LECTURE NOVEL THERAPEUTIC STRATEGIES OF ALLERGIC AND IMMUNOLOGIC DISORDERS.Transactions of the American Clinical and Climatological Association · 2018Review
- State of play and clinical prospects of antibody gene transfer.Journal of translational medicine · 2017Review
- Biologics to treat substance use disorders: Current status and new directions.Human vaccines & immunotherapeutics · 2016Review
- Negatively Charged Carbon Nanohorn Supported Cationic Liposome Nanoparticles: A Novel Delivery Vehicle for Anti-Nicotine Vaccine.Journal of biomedical nanotechnology · 2015Article
- Engineering humoral immunity as prophylaxis or therapy.Current opinion in immunology · 2015Review
- Scientific overview: 2013 BBC plenary symposium on tobacco addiction.Drug and alcohol dependence · 2014Article
- Review
- New directions in nicotine vaccine design and use.Advances in pharmacology (San Diego, Calif.) · 2014Review
- AAV Vectors Vaccines Against Infectious Diseases.Frontiers in immunology · 2014Review
- Addiction science: Uncovering neurobiological complexity.Neuropharmacology · 2014Review
- An AAV vector-mediated gene delivery approach facilitates reconstitution of functional human CD8+ T cells in mice.PloS one · 2014Article
- Enhancing Children against Unhealthy Behaviors-An Ethical and Policy Assessment of Using a Nicotine Vaccine.Public health ethics · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
Current strategies to help tobacco smokers quit have limited success as a result of the addictive properties of the nicotine in cigarette smoke. We hypothesized that a single administration of an adeno-associated virus (AAV) gene transfer vector expressing high levels of an anti-nicotine antibody would persistently prevent nicotine from reaching its receptors in the brain. To test this hypothesis, we constructed an AAVrh.10 vector that expressed a full-length, high-affinity, anti-nicotine antibody derived from the Fab fragment of the anti-nicotine monoclonal antibody NIC9D9 (AAVantiNic). In mice treated with this vector, blood concentrations of the anti-nicotine antibody were dose-dependent, and the antibody showed high specificity and affinity for nicotine. The antibody shielded the brain from systemically administered nicotine, reducing brain nicotine concentrations to 15% of those in naïve mice. The amount of nicotine sequestered in the serum of vector-treated mice was more than seven times greater than that in untreated mice, with 83% of serum nicotine bound to immunoglobulin G. Treatment with the AAVantiNic vector blocked nicotine-mediated alterations in arterial blood pressure, heart rate, and locomotor activity. In summary, a single administration of a gene transfer vector expressing a high-affinity anti-nicotine monoclonal antibody elicited persistent (18 weeks), high titers of an anti-nicotine antibody that obviated the physiologic effects of nicotine. If this degree of efficacy translates to humans, AAVantiNic could be an effective preventative therapy for nicotine addiction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.